A single intravenous dose of ketamine, a N-methlyl D-aspartate receptor (NMDAR) full antagonist, produces robust and rapid anti-obsessional effects in obsessive-compulsive disorder (OCD), 1, 2 but ketamine's side effects, including dissociation and nausea, may limit clinical use. 1, 3-5 Rapastinel (formerly GLYX-13), a putative NMDAR functional glycinesite partial agonist, has shown rapid anti-depressant activity without ketamine-like side effects, 6 and may be a new therapeutic strategy for OCD. We conducted the first test of the tolerability and potential efficacy of rapastinel administration in OCD. Specifically, we explored the drug's acute effects on obsessive-compulsive symptoms, depression and anxiety at 90 and 230 minutes post-infusion and at one week post-infusion.
Obsessive-Compulsive Scale [Y-BOCS 7, 8 ] score ≥16). Exclusion criteria included severe depression (Hamilton Depression Rating Scale [17 item version] >25), 9 current cognitive behavioral therapy, and other comorbid psychiatric or medical conditions that made participation unsafe.
Patients (n=7) received a single 3-5 minute IV push of rapastinel (dose=10 mg/kg). At baseline, 90, and 230 minutes post-infusion, patients self-rated the severity of their obsessions and compulsions (Y-BOCS Challenge Scale [YBOCCS], 10 12 ). Side effects of dissociation, 13 mania, 14 and psychosis 15 were assessed at baseline, 90, and 230 minutes post-infusion. At baseline and one week post-infusion, an independent evaluator, blind to study design, evaluated patients using the Y-BOCS, which appraises obsessive and compulsive symptoms over the prior week, and patients self-rated anxiety (BAI) and depression (BDI). Treatment response was defined a priori as ≥35% Y-BOCS reduction. 16 Outcomes were analyzed using a non-parametric Wilcoxon signed-rank matched-pairs test (α = .05, two-tailed) without adjustment for multiple comparisons given the exploratory nature of this study.
Results
All seven patients who received rapastinel completed the infusion. Patients had severe OCD symptoms: mean Y-BOCS score at baseline was 28.9 (SD = 4.4), with mean duration of illness of 24.9 years (SD = 10.6 years). The mean number of prior adequate serotonin reuptake inhibitor (SRI) trials was 3.4 (SD = 2.8, median = 3, with range 0-7). In our sample, 86% received at least one adequate trial of an SRI, 29% failed at least one prior adequate trial of antipsychotic augmentation, and 57% failed at least one prior adequate trial of cognitive behavior therapy with exposure and response prevention. Three of the seven OCD subjects (43%) had no other psychiatric comorbidity. Two subjects (29%) met criteria for comorbid generalized anxiety disorder. Two (29%) met criteria for comorbid major depression, with baseline HDRS scores of 11 (mild) and 14 (moderate). Compared to baseline, YBOCCS, BAI, and BDI scores were significantly lower at 90 and 230 minutes post-infusion (all p values < .05; Figure 1 and Supplementary Figure 1 Rapstinel was well tolerated. Of note, in contrast to participant reports in a prior study of IV ketamine in OCD, 1 participants did not report adverse events (e.g., dizziness, nausea, vomiting, or headache). Assessments of dissociation, mania, and psychosis were not significantly changed from baseline.
Conclusions/Discussion
The findings suggest that rapastinel is well tolerated in unmedicated OCD patients, as it is in patients with depression. 6 Specifically, rapastinel did not increase psychotomimetic effects following dosing in this sample of OCD patients, unlike ketamine in prior studies. 1, [3] [4] [5] In this small open-label sample, rapastinel had acute effects on obsessions and compulsions, anxiety and depression. However, rapastinel did not have significant effects on OCD symptoms one week post-infusion. To have clinical utility, glutamate modulators should refine molecular targets for rapid and sustained action while minimizing side effects. Mechanistic preclinical data suggests drugs like rapastinel 17 and ketamine's metabolite hydroxynorketamine 1, 8 that act on AMPA receptor modulation pathways may be promising therapeutic strategies.
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